Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Game-Changing Blood Test for Stroke Detection Could Bring Life-Saving Care to Patients

By LabMedica International staff writers
Posted on 20 May 2024

Stroke is the primary cause of disability globally and ranks as the second leading cause of death. More...

However, timely early intervention can prevent severe outcomes. Most strokes are ischemic, resulting from a blockage that disrupts blood flow to the brain. Large vessel occlusion (LVO) strokes, a severe form of ischemic stroke, occur when a major artery in the brain is obstructed. The brain cells begin to die within minutes due to the deprivation of oxygen and nutrients. LVO strokes are critical emergencies that necessitate rapid treatment with mechanical thrombectomy, a procedure that removes the obstruction. Now, a new test combines blood-based biomarkers with a clinical score to accurately identify patients suffering from LVO strokes.

Mechanical thrombectomy has revolutionized stroke treatment, potentially restoring individuals to full health as though they never experienced a stroke. The sooner this procedure is applied, the better the outcomes for patients. This groundbreaking technology, developed by researchers at Brigham and Women’s Hospital (Boston MA, USA), could significantly shorten the time to treatment worldwide. The study focused on two proteins in capillary blood: glial fibrillary acidic protein (GFAP), linked to brain bleeds and traumatic brain injury, and D-dimer. It was demonstrated that these biomarkers, in conjunction with the field assessment stroke triage for emergency destination (FAST-ED) scores, effectively identify LVO ischemic strokes and differentiate them from conditions like brain bleeds, which can present similar symptoms but require different treatments.

The researchers conducted a prospective, observational diagnostic accuracy study with a cohort of 323 stroke-coded patients from May 2021 to August 2022. They discovered that combining GFAP and D-dimer levels with FAST-ED scores within six hours from symptom onset allowed the test to detect LVO strokes with 93% specificity and 81% sensitivity. The test also successfully excluded all patients with brain bleeds, indicating potential future applications for detecting intracerebral hemorrhage in the field. This diagnostic tool shows promise for use in low- and middle-income countries, where advanced imaging might not be available, and for assessing traumatic brain injuries. Further research includes a new prospective trial to evaluate the test's effectiveness in ambulances, alongside an interventional trial designed to accelerate stroke patient triage by bypassing conventional imaging for direct intervention.

“We have developed a game-changing, accessible tool that could help ensure that more people suffering from stroke are in the right place at the right time to receive critical, life-restoring care,” said senior author Joshua Bernstock, MD, PhD, MPH, a clinical fellow in the Department of Neurosurgery at Brigham and Women’s Hospital.

Related Links:
Brigham and Women’s Hospital


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
MR-proADM Test
B•R•A•H•M•S MR-proADM KRYPTOR test
Immunofluorescence Analyzer
IFA System
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: A large, international study led by City of Hope found that the new, investigational liquid biopsy, called PANXEON, was highly sensitive in detecting stage 1 and 2 pancreatic cancer and had a low rate of false positives. The test was also able to identify high-grade dysplasia, a precancerous condition of the pancreas, potentially enabling intervention before cancer develops. (Photo courtesy of City of Hope)

Multi-Biomarker Blood Test Shows Promise for Early Pancreatic Cancer Detection

Pancreatic cancer has the lowest survival rates of any cancer, with only 14% of patients alive five years after diagnosis. The disease is typically discovered after it has spread, and an estimated 90%... Read more

Immunology

view channel
Image: Although many people harbor latent Epstein-Barr virus (EBV), growing evidence has linked the virus to MS pathobiology (Image Credit: Adobe Stock)

Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead

Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Pathology

view channel
image Credit: iStock

Tumor Budding Grading May Predict Chemotherapy Benefit in Resected Lung Squamous Cancer

Outcomes after resection for lung squamous cell carcinoma (SqCC) vary substantially, and the uneven benefit of adjuvant chemotherapy complicates postsurgical treatment decisions. Pathologic markers that... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.